Stay updated on Pembrolizumab for Genomic Instability Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedStudy status updated to Active, not recruiting and results posted with related documentation (Results First Submitted/Posted) and dates. ORR outcome measure details are added to the Results section.SummaryDifference4%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. This appears to be a minor front-end update with no visible changes to the study details or related content.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check65 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. Core study details, eligibility criteria, and contact information appear unchanged.SummaryDifference0.1%

- Check72 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is shown; no other content changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedThe page now includes a Show glossary option and new QC metadata labels, including Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the prior Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.